AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 396054
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 50 mg/kg praziquantel
Trial: 30121774
Drug: Good glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good glycemic control (HbA1c < 6.5%, FPG < 6.1 mmol/L)
Trial: 30121774
Drug: Insufficient glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insufficient glycemic control (HbA1c < 6.5%, FPG ≥ 6.1 mmol/L or HbA1c ≥ 6.5%, FPG < 6.1 mmol/L)
Trial: 30121774
Drug: Poor glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor glycemic control (HbA1c ≥ 6.5%, FPG ≥ 6.1 mmol/L)
Trial: 30121774
Drug: Insulin-exposed group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-exposed group
Trial: 30121774
Drug: Insufficient glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insufficient glycemic control with insulin exposure
Trial: 23419401
Drug: Resistant maltodextrin
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant maltodextrin (RMD) 9 g in tea, taken three times daily for 12 weeks
Trial: 16172203
Drug: Olanzapine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (7.5 to 30 mg per day)
Trial: 16172203
Drug: Perphenazine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (8 to 32 mg per day)
Trial: 16172203
Drug: Quetiapine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (200 to 800 mg per day)
Trial: 16172203
Drug: Risperidone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1.5 to 6.0 mg per day)
Trial: 16172203
Drug: Ziprasidone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (40 to 160 mg per day)
Trial: 8867876
Drug: ZK 93426
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 93426 (0.04 mg; 0.04 ml/kg)
Trial: 8867876
Drug: Scopolamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.5 mg; 1 ml)
Trial: 1363719
Drug: sulglycotide +
RxNorm normalized name: sulglicotide
DrugBank: Sulglicotide (DB13299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulglycotide + H2-antagonists
Trial: 6094445
Drug: Cefotaxime 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 3 g intravenously perioperatively
Trial: 6094445
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without prophylactic antibiotics
Trial: 30561539
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg GMZ2-CAF01
Trial: 30561539
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg GMZ2-CAF01
Trial: 28329753
Drug: High-intensity training
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity training (twice a week for 90 min with increasing loads)
Trial: 24108779
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml of DTaP
Trial: 24108779
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml of DTaP
Trial: 17554217
Drug: Tipranavir (TPV)
DrugBank: Tipranavir (DB00932)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tipranavir (TPV) 500 mg twice daily or 1000 mg twice daily with ritonavir 100 mg twice daily
Trial: 17554217
Drug: High-dose TPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose TPV/r
Trial: 17554217
Drug: Low-dose TPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose TPV/r
Trial: 11181397
Drug: Intravenous itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous itraconazole for 7 days followed by oral itraconazole solution at 200 mg twice daily for 14 days
Trial: 11181397
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole solution at 200 mg once daily for 14 days
Trial: 11181397
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole solution at 200 mg twice daily for 14 days
Trial: 11181397
Drug: Intravenous itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous itraconazole for 7 days followed by oral itraconazole solution
Trial: 1350340
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo with clonidine
Trial: 2863295
Drug: Fenoldopam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam 200 mg
Trial: 2863295
Drug: Fenoldopam (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (various doses)
Trial: 29659539
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein concentrate (1.15 and 0.26 g/kg on game and training days, respectively)
Trial: 29659539
Drug: Energy‐matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy‐matched placebo (1.37 and 0.31 g/kg of carbohydrate on game and training days, respectively)
Trial: 26757216
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg citalopram
Trial: 24578545
Drug: Healthy control
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy control subjects (no medication)
Trial: 22534255
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg orally once daily for 7 days)
Trial: 22534255
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg orally once daily for 10 days)
Trial: 22534255
Drug: Gemigliptin monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemigliptin monotherapy
Trial: 22534255
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration with ketoconazole
Trial: 22534255
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration with rifampicin
Trial: 20824184
Drug: Apoptotic tumor-autologous
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apoptotic tumor-autologous dendritic cell vaccine
Trial: 12599083
Drug: IPT +
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPT + daily iron
Trial: 12599083
Drug: daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily iron
Trial: 10804679
Drug: Self-help manuals,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help manuals, incentives, and social support groups (G)
Trial: 3513329
Drug: Foaming antacid
RxNorm normalized name: Foaming Antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foaming antacid
Trial: 31919501
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy for 1 year
Trial: 9639076
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg methylphenidate
Trial: 21745792
Drug: Email addresses
RxNorm normalized name: human IgG2 monoclonal antibody directed against the mucosal addressin cell adhesion molecule
DrugBank: Ontamalimab (DB15298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Email addresses used for online financial management and daily checked email accounts
Trial: 19690278
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anesthesia with 6-mg hyperbaric bupivacaine 0.5%
Trial: 19690278
Drug: Bilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral spinal anesthesia with 6-mg hyperbaric bupivacaine 0.5%
Trial: 10912880
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (Voltaren) administered orally two times a day for 27 consecutive days
Trial: 9451346
Drug: 1.5% glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% glycine irrigation solution at 70 cm height
Trial: 9451346
Drug: 1.5% glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% glycine irrigation solution at 150 cm height
Trial: 31892533
Drug: NI-0101 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NI-0101 (5 mg/kg, every 2 weeks for 12 weeks)
Trial: 20420907
Drug: Calcitriol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.5 mug taken twice daily for one week)
Trial: 20420907
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) (200,000 IU weekly for 3 weeks)
Trial: 20420907
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo weekly for 3 weeks)
Trial: 12401856
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (12 mg before each dialysis session for 4 weeks)
Trial: 2387279
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available preparations (yeast Se)
Trial: 6803277
Drug: Pyridoxine plus
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine plus L-tryptophan
Trial: 28522374
Drug: NNZ-2566 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNZ-2566 (doses ranged from 6.0 to 100mg/kg orally and 0.1 to 30mg/kg intravenously)
Trial: 21091547
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg vitamin C/kg feed
Trial: 21091547
Drug: 400 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/kg or 800 mg vitamin C/kg feed
Trial: 21091547
Drug: 150‐800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150‐800 mg vitamin C/kg feed
Trial: 16514568
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (age- and sex-matched cohort undergoing capsule endoscopy for suspected small bowel disease)
Trial: 15485574
Drug: Bicarbonate-buffered Bicavera
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate-buffered Bicavera solution
Trial: 15485574
Drug: Lactate-containing Balance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate-containing Balance solution
Trial: 11145322
Drug: Zolpidem (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (10 mg daily for 15 nights)
Trial: 3663879
Drug: Theo-Dur 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-Dur 450 mg b.i.d.
Trial: 3663879
Drug: Theotrim 450
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theotrim 450 mg b.i.d.
Trial: 29016868
Drug: Lubiprostone 24
RxNorm normalized name: LUBIPROSTONE 24MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 24 mcg twice daily for 12 weeks
Trial: 20507310
Drug: PR-PASIII-PC (platelets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR-PASIII-PC (platelets stored in platelet additive solution with pathogen reduction)
Trial: 20507310
Drug: PASIII-PC (platelets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PASIII-PC (platelets stored in platelet additive solution without pathogen reduction)
Trial: 3044091
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir capsules, five times per day for five days
Trial: 3044091
Drug: Topical 5
RxNorm normalized name: urea topical 50% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5 percent acyclovir in a modified aqueous cream base
Trial: 3044091
Drug: Topical 5
RxNorm normalized name: urea topical 50% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5 percent acyclovir in a polyethylene base
Trial: 3044091
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of oral acyclovir
Trial: 28758078
Drug: Superoposterior transforaminal
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superoposterior transforaminal epidural steroid injection (SP TFESI) with 1 mL of contrast material followed by steroid injection
Trial: 26311810
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d creatine
Trial: 26311810
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d creatine plus 400 μg/d folic acid
Trial: 26311810
Drug: 400 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg/d folic acid
Trial: 24063842
Drug: Diuretics in
RxNorm normalized name: OTHER DIURETICS in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics in patients with HFrEF
Trial: 12492792
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 0.2% plus sufentanil 0.2 micro g ml‐1, at 5 ml h‐1
Trial: 12492792
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral block with the same analgesic mixture
Trial: 12492792
Drug: Continuous intraarticular
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intraarticular infusion of ropivacaine 0.2% plus sufentanil 0.2 micro g ml‐1, at 5 ml h‐1
Trial: 10692189
Drug: Midazolam (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.05 mg/kg up to 2 mg)
Trial: 9348574
Drug: UFT 400
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 400 mg/day for 6 months plus prednimustine 60 mg/m2 for 7 consecutive days, every 28 days in 6 cycles (arm B)
Trial: 9348574
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day for 1 year plus UFT 400 mg/day for 6 months (arm B)
Trial: 9348574
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day for 1 year (arm A)
Trial: 8122356
Drug: Cisapride (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.1 mg/kg bw intramuscularly at 8‐h intervals)
Trial: 3537899
Drug: Dyazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyazide (50 mg triamterene and 25 mg hydrochlorothiazide)
Trial: 20164315
Drug: Soy milk
RxNorm normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy milk (16.98 mg genistein and 5.40 mg daidzein aglycone equivalents per dose)
Trial: 20164315
Drug: Soy supplement
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplement (5.27 mg genistein and 17.56 mg daidzein aglycone equivalents per dose)
Trial: 18788506
Drug: Cefepime 1
RxNorm normalized name: cefepime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 1 g q12 h and clindamycin 900 mg q8 h (group 2)
Trial: 18788506
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g q12 h and clindamycin 900 mg q8 h (group 1)
Trial: 16128647
Drug: Implantable drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable drug delivery system (IDDS)
Trial: 11892681
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment using TherMatrx TMx-2000
Trial: 8088613
Drug: Standard-dose salvage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose salvage chemotherapy
Trial: 7510351
Drug: 6 million
RxNorm normalized name: INTERFERON ALFA-2A,RECOMBINANT 6 MILLION UNT/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 million kallikrein inactivator units of aprotinin (high-dose group)
Trial: 7510351
Drug: 2 million
RxNorm normalized name: Carticel 12 million cells/vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 million kallikrein inactivator units of aprotinin (low-dose group)
Trial: 7510351
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (high-dose, low-dose, control)
Trial: 4395906
Drug: Isoprenaline 400
RxNorm normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline 400 μg
Trial: 4395906
Drug: Other bronchodilator
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other bronchodilator aerosols (doses adjusted to match peak response of isoprenaline)
Trial: 30312378
Drug: Method 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method 3 (weighted trial's subgroup-specific treatment effects)
Trial: 23269773
Drug: Uncertainty management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncertainty management intervention (scripted CD and guide booklet, supplemented by four scripted, 20-minute weekly training calls)
Trial: 23269773
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control condition (four scripted, 20-minute weekly training calls)
Trial: 17919835
Drug: Definitive radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Definitive radiotherapy with or without concurrent chemotherapy
Trial: 10230191
Drug: Naltrexone, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone, 1.0 mg/kg, administered daily for 2 weeks
Trial: 10230191
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered daily for 2 weeks
Trial: 6411791
Drug: Intravenous mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous mixture of eight essential l-amino acids, hypertonic dextrose, and vitamins
Trial: 27659879
Drug: CSL112 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (6 g)
Trial: 26563497
Drug: Salidroside (Sal)
RxNorm normalized name: Salicoside
DrugBank: Salicin (DB19357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salidroside (Sal) 20 mg/kg
Trial: 26563497
Drug: Salidroside (Sal)
RxNorm normalized name: Salicoside
DrugBank: Salicin (DB19357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salidroside (Sal) 40 mg/kg
Trial: 26563497
Drug: Clopidogrel (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (7.5 mg/kg)
Trial: 23091157
Drug: T4 with
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 with commercially available synbiotic Duolac, containing 500 cfu of both Lactobacillus acidophilus and Streptococcus faecium with the addition of lactose (0.001 mg/embryo)
Trial: 2672868
Drug: Epidural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural diamorphine (5 mg)
Trial: 17894913
Drug: Intramuscular diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diamorphine (5 mg)
Trial: 9684386
Drug: 8 mg/day
RxNorm normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/day buprenorphine
Trial: 11906798
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day buprenorphine
Trial: 11906798
Drug: 4 mg/day
RxNorm normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/day buprenorphine
Trial: 9684386
Drug: 16 mg/day
RxNorm normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/day buprenorphine
Trial: 8210019
Drug: Low-dose epidural
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose epidural anaesthesia using 0.375% bupivacaine
Trial: 2702250
Drug: Alipase (P)
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alipase (P) - 9 capsules/day
Trial: 21969870
Drug: Placebo (Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Control group from the Vaccine Trial)
Trial: 18098357
Drug: Mid-axial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-axial injection technique (MAI technique)
Trial: 18098357
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection technique (CI technique)
Trial: 16270608
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) via propofol and remifentanil infusion